160 related articles for article (PubMed ID: 22468098)
1. Iron overload during follow-up after tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma.
Bae SJ; Kang C; Sung KW; Chueh HW; Son MH; Lee SH; Yoo KH; Koo HH
J Korean Med Sci; 2012 Apr; 27(4):363-9. PubMed ID: 22468098
[TBL] [Abstract][Full Text] [Related]
2. Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors.
Chueh HW; Sung KW; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ
Pediatr Blood Cancer; 2012 Mar; 58(3):441-7. PubMed ID: 21638755
[TBL] [Abstract][Full Text] [Related]
3. Hematologic recovery after tandem high-dose chemotherapy and autologous stem cell transplantation in children with high-risk solid tumors.
Son MH; Kim DH; Lee SH; Yoo KH; Sung KW; Koo HH; Kim JY; Cho EJ; Kang ES; Kim DW
J Korean Med Sci; 2013 Feb; 28(2):220-6. PubMed ID: 23400387
[TBL] [Abstract][Full Text] [Related]
4. Tandem high-dose chemotherapy and autologous stem cell transplantation in young children with atypical teratoid/rhabdoid tumor of the central nervous system.
Park ES; Sung KW; Baek HJ; Park KD; Park HJ; Won SC; Lim DH; Kim HS
J Korean Med Sci; 2012 Feb; 27(2):135-40. PubMed ID: 22323859
[TBL] [Abstract][Full Text] [Related]
5. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
7. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
Vallejo C; Batlle M; Vázquez L; Solano C; Sampol A; Duarte R; Hernández D; López J; Rovira M; Jiménez S; Valcárcel D; Belloch V; Jiménez M; Jarque I;
Haematologica; 2014 Oct; 99(10):1632-7. PubMed ID: 24997153
[TBL] [Abstract][Full Text] [Related]
8. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Porter JB; Lin KH; Beris P; Forni GL; Taher A; Habr D; Domokos G; Roubert B; Thein SL;
Eur J Haematol; 2011 Oct; 87(4):338-48. PubMed ID: 21649735
[TBL] [Abstract][Full Text] [Related]
9. Renal function after tandem high-dose chemotherapy and autologous stem cell transplantation in children with Wilms tumor.
Lee SH; Paik KH; Sung KW; Son MH; Yoo KH; Koo HH; Kim JY; Cho EJ
Pediatr Transplant; 2011 Dec; 15(8):855-60. PubMed ID: 22060039
[TBL] [Abstract][Full Text] [Related]
10. Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.
Sung KW; Lim DH; Son MH; Lee SH; Yoo KH; Koo HH; Kim JH; Suh YL; Joung YS; Shin HJ
Neuro Oncol; 2013 Mar; 15(3):352-9. PubMed ID: 23258845
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Taher A; Cappellini MD; Vichinsky E; Galanello R; Piga A; Lawniczek T; Clark J; Habr D; Porter JB
Br J Haematol; 2009 Dec; 147(5):752-9. PubMed ID: 19764988
[TBL] [Abstract][Full Text] [Related]
12. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
[TBL] [Abstract][Full Text] [Related]
14. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
17. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
[TBL] [Abstract][Full Text] [Related]
20. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
